Jeff Borghoff speaks out on Biogen drug for Alzheimer's
The FDA is about to decide whether it will approve the first new drug for the treatment of Alzheimer’s in almost two decades. Jeff Borghoff fervently hopes the answer is yes. He has early onset Alzheimer's and has been taking the drug for years. Today he makes the case for why the drug aducanumab deserves approval.
Read my full story on Jeff Borghoff and the FDA's impending decision on aducanumab here: www.nj.com/healthfit/2021/05/...
Learn more about Jeff and his advocacy on issues affecting people with cognitive impairment by visiting his website: borghoff.com/
Visit the Go Cogno website here: gocogno.com/
Пікірлер: 4
$56,000:year. Injected and infused. Only for mild or early stages. Side effects brain swelling , headaches in some . Results underwhelming.
@GoCognocom
2 жыл бұрын
Those are all fair concerns about drug, being considered as Medicare decides whether it will cover Aduhelm, but in fairness, it should be noted that after public outrage over the cost of the drug, Biogen announced it would halve the annual cost to $28,000.
@donnaallgaier-lamberti3933
2 ай бұрын
I assume that this is NOT covered by Medicare or conventional insurances, am I correct?